Annual report [Section 13 and 15(d), not S-K Item 405]

REVENUES

v3.25.4
REVENUES
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 10 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below:

 

                 
   

Year ended 

December 31, 

  
    2025   2024  
Tonmya   $ 1,421   $ —  
Zembrace Symtouch 9,314 8,546
Tosymra     2,372     1,548  
Total product revenues   $ 13,107   $ 10,094  

 

All sales were generated in the United States.

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $8.9 million at December 31, 2025, $1.0 million of which was recorded as a reduction to accounts receivable and $7.9 million recorded as a component of accrued expenses. Our provision for gross-to-net allowances was $4.5 million at December 31, 2024, of which $0.8 million was recorded as a reduction to accounts receivable and $3.7 million was recorded as a component of accrued expenses.